Inactivating LKB1/STK11 mutations generally cause poor response to anti-PD-1 monoclonal antibodies, even if they correlate with an elevated tumor mutational burden (TMB) and an increased number of neoantigens [102]. This evidence concerns the gene STK11 and neoplasm.